Nanotechnology offers a transformative platform capable of improving drug pharmacokinetics, biodistribution, and tumor selectivity while minimizing systemic toxicity.9 Various nanocarriers including liposomes, micelles, dendrimers, and polymeric nanoparticles have been explored for drug delivery, among which human serum albumin (HSA)-based nanoparticles have attracted particular attention.10 This evidence concerns the gene ALB and neoplasm.